
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is positioned for success as they have a strong pipeline of drug candidates, with promising results for their lead assets NEO100 and NEO212. The use of POH in these treatments provides a novel approach to targeting CNS cancers, and the company's broad patent portfolio gives them a competitive advantage in the market. Despite facing financial challenges, NeOnc has a dedicated team and is working towards FDA approval, positioning themselves for future growth and potential partnerships.
Bears say
NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company's lead products, NEO100 and NEO212, aim to treat difficult-to-treat brain cancers and have shown promising anti-tumor activity in highly treatment-experienced patients. However, there is significant technical risk in dosing and delivery, and the company's pipeline is still in early stages with a 2031 projected market entry. Additionally, the potential safety concerns and limited reach of these drugs could limit their effectiveness in certain types of brain tumors, especially those located deep in the brain. Overall, the uncertain timeline and potential limitations on efficacy lead to a negative outlook on NeOnc Technologies Hldgs's stock.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares